EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The data demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma, with high disease-free survival rates reported. Investigators concluded that the combination of efti, KEYTRUDA, and radiotherapy as neoadjuvant therapy shows promise for further trials in this patient group. Further analyses will be presented in a poster discussion session at the meeting, with additional announcements expected from the company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immutep
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
- IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
- Upcoming Poster Presentations at CTOS and ESMO IO 2026
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Receives A$2.16 million French R&D Tax Incentive
Later from Immutep
- Immutep Expands US Patents for Efti Combination Therapies
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep